New Evidence With BTK Inhibitor Therapy in CLL From EHA 2023

In this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at EHA 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL). The discussion includes analyses of:CLL12: final results of the phase III trial of ibrutinib vs placebo in asymptomatic, treatment-naive CLLSEQUOIA: extended follow-up of zanubrutinib vs BR in treatment-naive CLLCAPTIVATE: 4-year follow-up from the fixed duration cohort of ibrutinib plus venetoclax in CLL/small lymphocytic lymphomaPhase II trial of acalabrutinib plus obinutuzumab in treatment-naive CLLBRUIN: genomic evaluation of resistance to pirtobrutinib in BTK inhibitor‒pretreated CLLPresenters:Catherine C. Coombs, MD, MSAssociate Clinical ProfessorDivision of Hematology/Oncology, Department of MedicineUCI HealthOrange, CaliforniaToby Eyre, MBChB, MDHonorary Senior LecturerHematology and CancerUniversity of OxfordConsultant HematologistDepartment of HematologyHematology and Cancer Centre, Oxford University Hospitals NHS Foundation TrustOxford, United Kingdom 

There are no comments yet.

Please log in to write the first comment.